Skip to main content
Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · IEX Real-Time Price · USD
10.96
-0.26 (-2.27%)
May 20, 2024, 10:10 AM EDT - Market open

Cidara Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018 - 2013
Revenue
63.9164.4549.5712.0720.92
Upgrade
Revenue Growth (YoY)
-0.84%30.01%310.81%-42.30%-
Upgrade
Cost of Revenue
1.520000
Upgrade
Gross Profit
62.3864.4549.5712.0720.92
Upgrade
Selling, General & Admin
18.3320.5518.7415.916.24
Upgrade
Research & Development
68.5377.4173.0968.0246.4
Upgrade
Operating Expenses
86.8797.9591.8383.9262.64
Upgrade
Operating Income
-24.48-33.5-42.26-71.85-41.72
Upgrade
Interest Expense / Income
000.210.26-0.22
Upgrade
Other Expense / Income
-2-0.19---0.41
Upgrade
Pretax Income
-22.49-33.31-42.47-72.11-41.09
Upgrade
Income Tax
0.440.27000
Upgrade
Net Income
-22.93-33.58-42.47-72.11-41.09
Upgrade
Preferred Dividends
0002.760
Upgrade
Net Income Common
-22.93-33.58-42.47-74.87-41.09
Upgrade
Shares Outstanding (Basic)
43321
Upgrade
Shares Outstanding (Diluted)
43321
Upgrade
Shares Change
25.15%33.18%26.22%38.83%15.71%
Upgrade
EPS (Basic)
-5.20-9.60-16.20-36.00-27.40
Upgrade
EPS (Diluted)
-5.20-9.60-16.20-36.00-27.40
Upgrade
Free Cash Flow
-22.94-28.59-25.27-54.6-28.57
Upgrade
Free Cash Flow Per Share
-5.25-8.19-9.64-26.27-19.09
Upgrade
Gross Margin
97.62%100.00%100.00%100.00%100.00%
Upgrade
Operating Margin
-38.31%-51.98%-85.24%-595.42%-199.49%
Upgrade
Profit Margin
-35.88%-52.11%-85.67%-620.48%-196.47%
Upgrade
Free Cash Flow Margin
-35.89%-44.36%-50.98%-452.45%-136.59%
Upgrade
EBITDA
-21.21-32.19-42.07-71.56-40.99
Upgrade
EBITDA Margin
-33.19%-49.94%-84.86%-593.05%-195.96%
Upgrade
Depreciation & Amortization
1.281.120.190.290.33
Upgrade
EBIT
-22.49-33.31-42.26-71.85-41.31
Upgrade
EBIT Margin
-35.19%-51.69%-85.24%-595.42%-197.53%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).